These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9746904)

  • 1. Modulating excitatory synaptic neurotransmission: potential treatment for neurological disease?
    Yamada KA
    Neurobiol Dis; 1998 Aug; 5(2):67-80. PubMed ID: 9746904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of positive AMPA receptor modulators in the treatment of neurological disease.
    Yamada KA
    Expert Opin Investig Drugs; 2000 Apr; 9(4):765-78. PubMed ID: 11060708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMPA receptor regulation mechanisms: future target for safer neuroprotective drugs.
    Jayakar SS; Dikshit M
    Int J Neurosci; 2004 Jun; 114(6):695-734. PubMed ID: 15204061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator.
    Baumbarger PJ; Muhlhauser M; Zhai J; Yang CR; Nisenbaum ES
    J Pharmacol Exp Ther; 2001 Jul; 298(1):86-102. PubMed ID: 11408529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMPA receptor modulators have different impact on hippocampal pyramidal cells and interneurons.
    Xia YF; Arai AC
    Neuroscience; 2005; 135(2):555-67. PubMed ID: 16125852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors.
    Shemer I; Holmgren C; Min R; Fülöp L; Zilberter M; Sousa KM; Farkas T; Härtig W; Penke B; Burnashev N; Tanila H; Zilberter Y; Harkany T
    Eur J Neurosci; 2006 Apr; 23(8):2035-47. PubMed ID: 16630051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanism of action of aniracetam at synaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors: indirect and direct effects on desensitization.
    Lawrence JJ; Brenowitz S; Trussell LO
    Mol Pharmacol; 2003 Aug; 64(2):269-78. PubMed ID: 12869631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in positive allosteric modulators of the AMPA receptor.
    Morrow JA; Maclean JK; Jamieson C
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):571-9. PubMed ID: 17002217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporospatial coupling of networked synaptic activation of AMPA-type glutamate receptor channels and calcium transients in cultured motoneurons.
    Jahn K; Grosskreutz J; Haastert K; Ziegler E; Schlesinger F; Grothe C; Dengler R; Bufler J
    Neuroscience; 2006 Nov; 142(4):1019-29. PubMed ID: 16949760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of AMPA receptor desensitization and the side effects of a DMSO vehicle on reticulospinal EPSPs and locomotor activity.
    Tsvyetlynska NA; Hill RH; Grillner S
    J Neurophysiol; 2005 Dec; 94(6):3951-60. PubMed ID: 16107533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diazoxide derivative IDRA 21 enhances ischemic hippocampal neuron injury.
    Yamada KA; Covey DF; Hsu CY; Hu R; Hu Y; He YY
    Ann Neurol; 1998 May; 43(5):664-9. PubMed ID: 9585363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [AMPA receptor desensitization and fast excitatory synaptic transmission].
    Lu T; Yang XL
    Sheng Li Ke Xue Jin Zhan; 1997 Jul; 28(3):197-202. PubMed ID: 11038724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors.
    Ryder JW; Falcone JF; Manro JR; Svensson KA; Merchant KM
    J Pharmacol Exp Ther; 2006 Oct; 319(1):293-8. PubMed ID: 16803862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The AMPA receptor as a therapeutic target: current perspectives and emerging possibilities.
    Mellor IR
    Future Med Chem; 2010 May; 2(5):877-91. PubMed ID: 21426207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMPA receptor modulators as cognitive enhancers.
    Lynch G
    Curr Opin Pharmacol; 2004 Feb; 4(1):4-11. PubMed ID: 15018832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metabotropic glutamate receptors: new molecular targets in the treatment of neurological and psychiatric diseases].
    Luján-Miras R
    Rev Neurol; 2005 Jan 1-15; 40(1):43-53. PubMed ID: 15696426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postsynaptic modulation of AMPA receptor-mediated synaptic responses and LTP by the type 3 ryanodine receptor.
    Shimuta M; Yoshikawa M; Fukaya M; Watanabe M; Takeshima H; Manabe T
    Mol Cell Neurosci; 2001 May; 17(5):921-30. PubMed ID: 11358488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postnatal aniracetam treatment improves prenatal ethanol induced attenuation of AMPA receptor-mediated synaptic transmission.
    Wijayawardhane N; Shonesy BC; Vaglenova J; Vaithianathan T; Carpenter M; Breese CR; Dityatev A; Suppiramaniam V
    Neurobiol Dis; 2007 Jun; 26(3):696-706. PubMed ID: 17493826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Input- and subunit-specific AMPA receptor trafficking underlying long-term potentiation at hippocampal CA3 synapses.
    Kakegawa W; Tsuzuki K; Yoshida Y; Kameyama K; Ozawa S
    Eur J Neurosci; 2004 Jul; 20(1):101-10. PubMed ID: 15245483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.